873056-16-7

Upstream product

• 231938-20-8 spiro[indene-1,4'-piperidin]-3(2H)-one hydrochloride 
• 100-39-0 benzyl bromide 
• 95-13-6 1-indene 
• 185525-42-2 tert-butyl 3-hydroxy-2,3-dihydrospiro[indene-1,4’-piperidine]-1‘-carboxylate 
• 137419-24-0 1'-(tert-butyloxycarbonyl)spiro<1H-indene-1,4'-piperidine> 
• 159634-59-0 2,3-dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester 

Downstream Products

• 873056-18-9 1,2,3,4-tetrahydroquinolin-4-spiro-4'-(N'-benzylpiperidine) 
• 947724-88-1 1-benzyl-N,N-dimethyl-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinoline]-1'-carboxamide 

Relevant academic research and scientific papers

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarnic receptors of formula (I). The present invention also provides impositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.